| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥83.5B | ¥77.6B | +7.6% |
| Operating Income | ¥16.7B | ¥13.4B | +24.3% |
| Ordinary Income | ¥17.2B | ¥13.8B | +24.4% |
| Net Income | ¥11.7B | ¥9.4B | +25.3% |
| ROE | 8.7% | 6.9% | - |
FY2025 Q3 cumulative results (9-month period ending January 2026): Revenue of 83.5B yen (YoY +7.6%), Operating Income of 16.7B yen (YoY +24.3%), Ordinary Income of 17.2B yen (YoY +24.4%), and Net Income of 11.7B yen (YoY +25.3%). The company achieved strong profit growth exceeding revenue growth, demonstrating operational leverage. All three business segments posted revenue increases, with Health and Medical Equipment showing particularly robust growth at +14.0% YoY. Operating margin improved to 20.0% from the prior year, with gross profit margin maintained at a high level of 43.9%. Basic EPS increased significantly to 224.00 yen from 168.70 yen (YoY +32.8%), reflecting strong earnings quality at the bottom line.
Revenue increased 5.9B yen to 83.5B yen (YoY +7.6%), driven by broad-based growth across all three reporting segments. Science Equipment and Facility contributed 43.8B yen (+6.4% YoY), representing 52.4% of total revenue as the core business segment. Health and Medical Equipment recorded 20.2B yen (+14.0% YoY), the highest growth rate among segments, while Industrial Equipment generated 19.5B yen (+4.0% YoY). Geographic revenue breakdown shows domestic Japan at 62.6B yen representing 75.0% of revenue from contracts with customers, Asia at 12.3B yen, and Other regions at 3.1B yen. The company also recognized 5.5B yen in other revenue primarily from lease transactions. Cost of sales increased 1.5B yen to 46.8B yen, but gross profit expanded 4.4B yen to 36.6B yen, maintaining gross margin at 43.9% compared to 41.6% in the prior period. SG&A expenses rose 0.8B yen to 19.1B yen (22.9% of revenue), controlled below revenue growth rate, resulting in operating leverage. Operating income improved 3.3B yen to 16.7B yen with operating margin expanding 3.1 percentage points to 20.0%. Non-operating income contributed 0.5B yen, primarily from interest income of 0.3B yen (including securities interest of 0.1B yen) and dividend income of 0.1B yen. Non-operating expenses were minimal at 30M yen, resulting in ordinary income of 17.2B yen. Extraordinary items were negligible with extraordinary income of 16M yen from asset sales and extraordinary loss of 2M yen from asset disposals. Income tax expense of 5.4B yen represented an effective tax rate of 31.6%. Net income attributable to owners of parent reached 11.7B yen, with 0.5B yen attributable to non-controlling interests. The 0.5B yen gap between operating income (16.7B yen) and ordinary income (17.2B yen) represents 3.0% benefit from net non-operating income, indicating minimal extraordinary financial factors. This results in a revenue up/profit up pattern, with profit growth significantly outpacing revenue growth due to margin expansion and operational efficiency improvements.
Science Equipment and Facility generated revenue of 43.8B yen (YoY +6.4%) and segment profit of 9.1B yen, representing the largest business at 52.4% of total revenue. This core business segment demonstrated stable growth with segment profit margin of 20.7%. Health and Medical Equipment recorded revenue of 20.2B yen (YoY +14.0%) and segment profit of 3.9B yen, showing the strongest growth momentum among all segments with a segment profit margin of 19.2%. The segment includes 5.5B yen in other revenue from lease transactions. Industrial Equipment achieved revenue of 19.5B yen (YoY +4.0%) and segment profit of 4.2B yen, with segment profit margin of 21.6% being the highest among the three segments. The profitability differential indicates that Industrial Equipment operates at premium margins despite being the smallest segment by revenue. All three segments contributed positively to consolidated profit growth, with total segment profit of 17.2B yen aligning with consolidated ordinary income, indicating no material adjustments at the corporate level.
[Profitability] ROE of 8.7% reflects improved profitability, with operating margin at 20.0% representing a strong improvement from prior year levels. Net profit margin of 14.1% demonstrates efficient conversion from revenue to bottom line. Gross profit margin of 43.9% indicates robust pricing power and product mix. [Cash Quality] Cash and deposits of 76.7B yen provide substantial liquidity, covering short-term debt multiple times with no material interest-bearing debt disclosed. Working capital quality shows concerns with inventory turnover at 123 days (inventory increased 37.1% YoY to 15.8B yen), accounts receivable turnover at 67 days, and accounts payable at 54 days, resulting in a cash conversion cycle of 193 days indicating deteriorating working capital efficiency. [Investment Efficiency] Asset turnover of 0.471 reflects the capital-intensive nature of the business and elevated current asset levels representing 77.4% of total assets. Return on assets improved YoY supported by margin expansion. [Financial Health] Equity ratio of 76.2% indicates conservative capital structure, improved from 73.1% in the prior year. Current ratio of 440.0% and quick ratio of 389.5% demonstrate exceptional liquidity position. Debt-to-equity ratio of 0.31 reflects minimal leverage with interest coverage ratio of 2,528.8 times indicating negligible financial risk from debt service obligations.
Cash and deposits decreased 6.8B yen YoY to 76.7B yen, though maintaining a robust absolute level representing 43.3% of total assets. The decline reflects strategic deployment of cash rather than liquidity constraints. Working capital movements show significant changes: inventories increased 4.3B yen (37.1% YoY) to 15.8B yen, indicating substantial inventory buildup that exceeds revenue growth and warrants close monitoring for potential obsolescence or demand forecasting issues. Trade receivables decreased 2.1B yen to 15.3B yen, improving collection efficiency. Trade payables increased 2.9B yen (71.4% YoY) to 6.9B yen, suggesting extended supplier payment terms that support liquidity. Contract liabilities remained stable at 6.9B yen. The company holds no short-term investment securities compared to 12.0B yen in the prior period, indicating a shift in treasury management strategy. Investment securities increased to 11.2B yen from 9.8B yen, representing strategic long-term holdings. Deferred tax assets decreased slightly to 4.0B yen from 4.1B yen. With comprehensive income of 12.0B yen including valuation gains on securities of 0.3B yen, underlying cash generation capability remains sound despite working capital headwinds. Cash coverage of current liabilities stands at 2.5 times, providing substantial financial flexibility.
Ordinary income of 17.2B yen versus operating income of 16.7B yen shows net non-operating contribution of approximately 0.5B yen, representing 0.6% of revenue and 3.0% enhancement to operating earnings. This comprises primarily financial income from interest of 0.3B yen including securities interest of 0.1B yen, dividend income of 0.1B yen, and other non-operating income of 31M yen, partially offset by minimal non-operating expenses of 30M yen including interest expense of 7M yen and foreign exchange losses of 12M yen. The non-operating income composition is stable and recurring in nature, consisting of returns on substantial cash holdings and investment securities. Extraordinary items totaling net 14M yen (16M yen gain from asset sales less 2M yen disposal loss) represent only 0.02% of revenue and are truly non-recurring, having no material impact on core earnings quality. Comprehensive income of 12.0B yen includes 0.3B yen in valuation gains on securities (other comprehensive income), indicating net income of 11.7B yen closely aligns with comprehensive income. The modest gap between operating income and net income of 5.0B yen primarily reflects income taxes of 5.4B yen at an effective rate of 31.6%, which is reasonable and consistent. With minimal extraordinary items, stable non-operating income structure, and negligible interest expense burden, earnings quality is assessed as high with strong recurring characteristics supported by the company's substantial cash position and conservative financial structure.
Progress against full-year guidance shows revenue at 75.6% (83.5B yen actual vs 110.4B yen forecast), operating income at 78.3% (16.7B yen vs 21.3B yen forecast), and ordinary income at 78.9% (17.2B yen vs 21.8B yen forecast) after nine months representing 75% of the fiscal year. The progress rates slightly exceed the standard 75% benchmark, indicating the company is tracking ahead of plan in profitability metrics despite revenue being in line. Full-year guidance implies Q4 revenue of 26.9B yen, operating income of 4.6B yen, and ordinary income of 4.6B yen, representing Q4 margins of 17.1% for operating income and 17.1% for ordinary income, modestly below the 20.0% operating margin achieved in the nine-month period. This suggests management anticipates either seasonal factors, increased costs, or conservative assumptions for the final quarter. Forecast EPS of 283.60 yen and dividend forecast of 138.00 yen remain unchanged from the original guidance with no revisions made this quarter. Net income attributable to owners is forecast at 14.9B yen for the full year, implying Q4 net income of 3.2B yen. The company has not revised forecasts despite strong Q3 performance, indicating either conservatism or anticipated headwinds in the remaining period. Contract liabilities of 6.9B yen represent approximately 62.4 days of revenue, providing some forward revenue visibility though not constituting formal order backlog.
Second quarter dividend of 146.00 yen has been paid, with full-year dividend forecast maintained at 138.00 yen per share, unchanged from prior guidance. Based on full-year forecast net income of 14.9B yen and forecast EPS of 283.60 yen, the implied payout ratio is 48.7% against forecast earnings, which is reasonable and sustainable. However, when comparing the annualized Q3 interim dividend of 146.00 yen against actual nine-month EPS of 224.00 yen, the payout would represent 65.2% of trailing earnings, indicating a higher distribution rate if the Q2 dividend pace continues. The prior year dividend was 83.00 yen per share, making the current forecast of 138.00 yen represent a 66.3% increase YoY, demonstrating significant shareholder return enhancement. With cash and deposits of 76.7B yen and strong operating profitability, dividend payment capacity is robust. No share buyback activity has been disclosed in the current period. Total shareholder return focuses on dividends with the payout ratio at forecast levels appearing sustainable given the strong balance sheet and cash generation, though monitoring of actual full-year earnings achievement against forecast will be important to confirm dividend coverage adequacy.
Segment concentration risk with Science Equipment and Facility representing 52.4% of revenue creates exposure to demand fluctuations in this single business area, though the company partially mitigates this through geographic and customer diversification within the segment. Working capital deterioration risk is evidenced by inventory increasing 37.1% YoY to 15.8B yen significantly outpacing revenue growth of 7.6%, combined with inventory turnover extending to 123 days and cash conversion cycle of 193 days, indicating potential demand forecasting misalignment, excess production, or product mix shifts that could result in future inventory write-downs or margin pressure from clearance sales if demand does not materialize as planned. Profitability sustainability risk stems from the gap between strong Q3 margin performance (20.0% operating margin) and implied Q4 guidance suggesting only 17.1% operating margin, with unclear drivers of the expected margin compression that could include seasonal factors, planned cost increases, or investments not yet reflected in year-to-date results, warranting close monitoring of whether Q3 profitability levels represent a sustainable new baseline or temporary peak.
[Industry Position] (Reference - Proprietary Analysis) Profitability metrics demonstrate strong competitive positioning with ROE of 8.7% aligning with the industry median of 8.1% for 2025-Q3, while operating margin of 20.0% significantly exceeds the industry median of 4.7% (industry IQR: 1.8%-12.4%), positioning the company in the top quartile for operational efficiency. Net profit margin of 14.1% substantially outperforms the industry median of 6.5% (industry IQR: 3.6%-13.5%), indicating superior earnings conversion capability. Financial health metrics show equity ratio of 76.2% well above the industry median of 52.3% (industry IQR: 35.5%-60.6%), reflecting conservative capitalization. Current ratio of 4.40 times exceeds the industry median of 2.03 times (industry IQR: 1.63-3.24), demonstrating exceptional liquidity strength. Efficiency metrics reveal mixed performance with asset turnover of 0.471 below the industry median of 0.82 (industry IQR: 0.44-1.06), indicating lower asset utilization efficiency partially driven by high cash holdings. Inventory turnover of 123 days significantly exceeds the industry median of 35 days (industry IQR: 15-87 days), flagging working capital efficiency as an area materially underperforming peer companies. Receivables turnover of 67 days compares to industry median of 47 days (industry IQR: 34-55 days), while payables turnover of 54 days is faster than industry median of 37 days (industry IQR: 31-85 days). Growth metrics show revenue growth of 7.6% YoY exceeding the industry median of 5.7% (industry IQR: -1.0%-11.6%), while EPS growth of 32.8% substantially outperforms the industry median of 24.0% (industry IQR: -28%-45%). Return on assets of 6.6% exceeds industry median of 4.6% (industry IQR: 1.8%-6.5%), and return on invested capital is competitive within industry parameters. Industry: Precision Instruments and Scientific Equipment (10 companies), Comparison period: FY2025-Q3, Source: Proprietary analysis of publicly available financial data.
Superior profitability positioning with operating margin of 20.0% and net margin of 14.1% significantly exceeding industry benchmarks demonstrates sustainable competitive advantages likely stemming from product differentiation, operational excellence, or favorable market positioning that should support continued strong earnings generation provided the company maintains market share. Conservative balance sheet with equity ratio of 76.2%, cash holdings of 76.7B yen, and minimal leverage provides substantial financial flexibility for growth investments, potential M&A activity, or enhanced shareholder returns, while simultaneously serving as a defensive buffer against business cycle volatility. Working capital efficiency deterioration requiring management attention is evidenced by inventory turnover of 123 days versus industry median of 35 days and overall cash conversion cycle of 193 days, representing a material operational gap where improvements could unlock significant cash generation and return on capital enhancement without requiring revenue growth, suggesting this should be a key focus area for operational improvement initiatives in coming periods.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.